Want to see HK:2297 full AI Analyst Report?
Rainmed Medical Limited (2297) AI Stock Analysis
Rainmed Medical Limited
(HKEX:2297)
The score is held down primarily by weak financial performance (shrinking revenue, negative margins, and ongoing cash burn) despite a relatively low-leverage balance sheet. Technicals show only tentative stabilization with a still-weak longer-term trend, while valuation remains unattractive due to losses and no indicated dividend support.
Rainmed Medical Limited (2297) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 241.03M
- Dividend Yield
- ―
- Average Volume (3M)
- 550.00K
- Price to Earnings (P/E)
- -3.0
- Beta (1Y)
- 0.39
- Revenue Growth
- 4.35%
- EPS Growth
- 43.23%
- Country
- Hong Kong
- Employees
- 208
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Rainmed Medical Limited Business Overview & Revenue Model
Company Description
Rainmed Medical Limited is a medical technology firm specializing in the creation, development, and market launch of advanced systems that utilize coronary angiography to assess fractional flow reserve (FFR) and the index of microvascular resistance...
How the Company Makes Money
Rainmed Medical Limited primarily makes money by selling medical devices and related consumables to healthcare providers (e.g., hospitals and clinics) and/or through medical-device distribution channels. Key revenue drivers typically include (i) sale...
Rainmed Medical Limited Financial Statement Overview
Summary
Overall fundamentals are weak: revenue has contracted sharply, profitability remains deeply negative with 2025 gross margin turning negative, and operating/free cash flow are persistently negative (ongoing cash burn). The balance sheet is a relative strength with modest leverage, but continued losses threaten durability.
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
21Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.46M | 19.18M | 39.82M | 73.22M | 83.60M | 81.20M |
| Gross Profit | 7.12M | 9.04M | 23.87M | 48.55M | 69.82M | 69.03M |
| EBITDA | -43.96M | -54.41M | -77.00M | -93.54M | -1.33B | -623.97M |
| Net Income | -66.93M | -77.08M | -113.50M | -115.83M | -1.35B | -633.64M |
Balance Sheet | ||||||
| Total Assets | 568.65M | 545.73M | 463.06M | 573.31M | 690.33M | 640.19M |
| Cash, Cash Equivalents and Short-Term Investments | 129.01M | 153.35M | 205.55M | 335.28M | 578.96M | 559.14M |
| Total Debt | 181.94M | 24.83M | 25.58M | 20.00M | 28.98M | 1.38B |
| Total Liabilities | 238.81M | 187.59M | 53.15M | 53.30M | 71.69M | 1.41B |
| Stockholders Equity | 330.26M | 357.54M | 407.00M | 515.05M | 618.64M | -774.48M |
Cash Flow | ||||||
| Free Cash Flow | -212.40M | -79.69M | -138.10M | -235.27M | -141.04M | -103.95M |
| Operating Cash Flow | -52.00M | -76.40M | -84.31M | -124.29M | -111.22M | -72.83M |
| Investing Cash Flow | -139.80M | 7.24M | 6.31M | 180.29M | -515.74M | -27.98M |
| Financing Cash Flow | 146.74M | 30.15M | 723.00K | -15.88M | 120.73M | 633.85M |
Rainmed Medical Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2297, the sentiment is Neutral. The current price of 0.17 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.17, and below the 200-day MA of 0.23, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 55.09 is Neutral, neither overbought nor oversold. The STOCH value of 70.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2297.
Rainmed Medical Limited Peers Comparison
Overall Rating
HK:161267Neutral
HK:666961.6Neutral
HK:223559Neutral- HK:229746Neutral
HK:221644Neutral
HK:250044Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1612 | 67Neutral | HKD 468.67M | 4.77 | 13.95% | 6.48% | 10.95% | 9.26% |
| HK:6669 | 62Neutral | HKD 1.64B | -27.72 | -3.50% | ― | 9.36% | -153.54% |
| HK:2235 | 59Neutral | HKD 2.82B | 27.65 | 4.08% | ― | 94.80% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2297 | 46Neutral | HKD 241.03M | -2.97 | -19.46% | ― | 4.35% | 43.23% |
| HK:2216 | 44Neutral | HKD 306.67M | -1.98 | -12.45% | ― | ― | ― |
| HK:2500 | 44Neutral | HKD 432.19M | -0.78 | -28.24% | ― | -38.15% | 25.70% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2297 | Rainmed Medical Limited | 0.17 | -0.12 | -40.69% | |
| HK:6669 | Acotec Scientific Holdings Limited | 5.22 | -6.87 | -56.82% | |
| HK:1612 | Vincent Medical Holdings Limited | 0.71 | -0.10 | -12.24% | |
| HK:2216 | Broncus Holding Corp. | 0.58 | -2.00 | -77.52% | |
| HK:2235 | MicroTech Medical (Hangzhou) Co., Ltd. Class H | 6.70 | -0.20 | -2.90% | |
| HK:2500 | Venus Medtech (Hangzhou), Inc. Class H | 0.98 | -1.77 | -64.36% |
Rainmed Medical Limited Corporate Events
Rainmed Medical reshapes board with director resignation and new appointment
Rainmed Medical Limited has announced the resignation of non-executive director Wang Lin, effective 4 September 2026, as he steps down to devote more time to other commitments. The board stated there is no disagreement associated with his departure a...
Rainmed Medical Details Board and Committee Structure
Rainmed Medical Limited has disclosed the composition of its board of directors, naming chairman Huo Yunfei and detailing a mix of executive, non-executive and independent non-executive directors. The announcement underscores the company’s gove...
Rainmed narrows interim loss as revenue and margins improve
Rainmed Medical Limited reported a 41.3% year-on-year rise in revenue to RMB14.7 million for the six months ended June 30, 2026, with gross profit up 82.4% and margin improving to 63.2%. Despite the stronger top-line and better profitability, the com...
Rainmed Medical Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Rainmed Medical Limited has scheduled a board meeting for August 31, 2026, to review and approve the unaudited interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider whether to recomme...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026